tbuckley/cabot-search huggingface dataset:
1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Authors: E. Castro, D. Laird, T. Dorff, S. Zhao, I.M. van Oort, D. Gasparro, F. Calabro', S. Pignata, L. Geczi, P. Barthelemy, D. Kilari, J.F. Hopkins, H-C. Chen, C.G. Healy, J. Chelliserry, G. Scagliotti, J.S. de Bono, N. Mehra, K. Fizazi
Journal: Annals of Oncology (2023)

TALAPRO-1 evaluated talazoparib in patients (pts) with mCRPC and homologous recombination repair (HRR) alterations (11-gene panel, including BRCA1/2, PALB2, and ATM), who had received at least a taxane-based chemotherapy regimen and progressed on ≥1 novel hormonal therapy. Primary endpoint was objective response rate (RECIST 1.1) by blinded independent central review. Exploratory biomarker analyses assessed ctDNA and its associations with antitumor activity. Serial ctDNA samples from Weeks (Wks) 1, 9, and 25, and Safety follow-up visit (SFUV) were assessed using FoundationOne Liquid CDx. Plasma tumor fraction (TF) was calculated based on tumor aneuploidy as described by Husain et al ( JCO Precis Oncol 2022; 6:e2200261). Data cut-off was September 4, 2020 (primary completion date). BRCA2 mutational complexity (variants/BRCA2m pts) was 18/16 (1.1), 12/10 (1.2), 62/11 (5.6), and 57/14 (4.1) at Wks 1, 9, and 25, and SFUV, respectively. At Wk 25, the median number of BRCA2 variants was 2 (range 1–18; 3 pts had ≥15 variants). Mutational complexity increased for BRCA1 and PALB2 by Wk 25 but remained unchanged for ATM. Of 26 evaluable pts, 7 cases of emergent variants in PARP1, PARP2, or PARP3 at Wk 25 and/or SFUV were detected. These included 5 cases of PARP1 variants predicted to truncate PARP1 and/or inhibit talazoparib binding, including 3 cases of A898T. 15/27 pts had TF quantifiable at Wk 1 (range 10−68%). Of these 15 pts, 10 had TF below limit of quantitation (BLQ; 10%), 1 had TF reduction ≥50%, and 4 had TF unchanged (change <50%) at Wk 9. Reductions to BLQ were seen in 4/4 with partial response, 2/2 with non-complete response/non-progressive disease, 3/5 with stable disease (an additional patient reduced ≥50%), and 1/4 with progressive disease. Increased mutational complexity of genes in the BRCA1-PALB2-BRCA2 axis and emergent PARP variants likely reflects selective pressure to escape talazoparib-mediated synthetic lethality and/or PARP trapping. Early reductions in TF were evident and numerically more common in pts with antitumor responses. Further exploration of emergent variants in HRR and PARP genes and of ctDNA burden are warranted.
1819P PSMA-BAT: Prospective biomarker trial of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) undergoing bipolar androgen therapy (BAT)
Authors: A.B. Lara Gongora, P. Isaacsson Velho, J.F. Gomes Marin, D.L.F. Jardim, L.T. Inoue, E.M. Coser, C.A. Buchpiguel, F. Galiza, M. Queiroz, A. Schuch, G.B. Grossman, F. Bettoni, A.A. Camargo, D.A. Bastos
Journal: Annals of Oncology (2023)
1731P Providing access to anticancer drugs within an armed conflict: The experience of Mission Kharkiv (MK) and Medecins Sans Frontieres (MSF) in Ukraine
Authors: S. Polozov, H. Marijon Jourdier, R. Shkavron-Filippenko, M. Boulay, A. Taconet, C. Bouillat, A. Brousse, D. Kocheharova, D. Vulpian, L. Averkova, Y. Bennadji, C. Ngo, C.M. Rieux
Journal: Annals of Oncology (2023)
1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: W. Kelly, D. Danila, C-C. Lin, J-L. Lee, N. Matsubara, P. Ward, A.J. Armstrong, D. Pook, M. Kim, T. Dorff, S. Fischer, Y-C. Lin, L.G. Horvath, C. Sumey, Z. Yang, G. Jurida, J. Connarn, H. Penny, J. Stieglmaier, L.J. Appleman
Journal: Annals of Oncology (2023)
1817P A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care
Authors: E. Diamond, C. Kwak, D. Orr, A. Bamidele, I.G. Jeong, A. Bessudo, C. Dunshee, S. Henderson, J.Y. Joung, S. Lee, J. Chaves, D. Slater, A. Patnaik, C. Pieczonka, W. Lee, Y.D. Choi, P. Guo, K. Ma, E. Cao, Y. Yue
Journal: Annals of Oncology (2023)
1788P Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial
Authors: K. Chang, X. Zhang, L. Xie, S. Wang, B. Shi, T. Sun, S. Wei, Z. Weng, S. Xia, B. Han, Z. Xu, J. Xing, D. Zhang, D. Xu, C. Du, C. He, Q. Wang, J. Lian, Q. Shi, D. Ye
Journal: Annals of Oncology (2023)
1770O Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium
Authors: P. Ravi, W. Xie, M.E. Buyse, S. Halabi, P.W. Kantoff, O. Sartor, G. Attard, N.W. Clarke, A. D'Amico, J. Dignam, N.D. James, K. Fizazi, S. Gillessen, W.R. Parulekar, H. Sandler, D. Spratt, M.R. Sydes, B. Tombal, S. Williams, C. Sweeney
Journal: Annals of Oncology (2023)
1776P Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Authors: M. Støyten, T. Knutsen, E. Stikkbakke, I. Agledahl, T. Wilsgaard, A-E. Eggen, E. Richardsen, E. Giovannucci, I. Thune, H. Sagstuen Haugnes
Journal: Annals of Oncology (2023)
1750P Knowledge and awareness of hepatitis B and C virus reactivation among oncologists in Dutch-speaking Belgium: The CHOICe trial (Chronic Hepatitis B/C screening in patients on immunosuppressive therapy and chemotherapy)
Authors: M. Coessens, C. Van de Bruaene, W. Verlinden, A. Geerts, V. Kruse, M. Aerts, S. Bourgeois, I. Colle, J. Maus, H. Orlent, L. Van Overbeke, C. Van Steenkiste, J. Schouten
Journal: Annals of Oncology (2023)
1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS
Authors: A.K. Morgans, C. Sweeney, C. Wallis, S. Halabi, A.J. Armstrong, A.F. Mohamed, P. Adorjan, F. Verholen, S. Srinivasan, M-O. Grimm
Journal: Annals of Oncology (2023)
1736P Young adult lung cancer demands more attention in a low-resource area: Bangladesh perspective
Authors: M.R. Islam, S. Siddiqua, M.R. ISLAM, B. Saha, M. Rahman, S.B. Al Ayub, A.A.M. Khan, A.T.M.K. Hasan, A. Hossain, M.J. Alam, N. Khatun, M.N. Karim
Journal: Annals of Oncology (2023)
1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Authors: S.J. Freedland, M.E. Gleave, U.F.F. De Giorgi, A. Rannikko, C. Pieczonka, S. Sridharan, K. Brasso, H. Woo, A. Gomez Caamaño, J. Saranchuk, L.T. Nordquist, U. Ferreira, Y. Tang, B. Rosbrook, G.P. Haas, M. Rosales, F. Zohren, N.D. Shore
Journal: Annals of Oncology (2023)
1753P Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Authors: C. Cardone, S. Facchini, F. Collina, M.R. Brogna, A. Daniele, R. Casaretti, A. Cassata, A. De Stefano, A. Nappi, F. Foschini, L. Silvestro, C. Romano, N. Zanaletti, F. Tatangelo, S. De Franciscis, A. Belli, F. Izzo, G. Ferrara, P. Delrio, A. Avallone
Journal: Annals of Oncology (2023)
1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study
Authors: J.N. Graff, M. Burotto, P.C. Fong, D. Pook, B. Zurawski, R. Manneh Kopp, J.E. Salinas, K. Bylow, G. Kramer, R. Ratta, M. Kwiatkowski, M. Retz, C. Kwak, J.A. Arranz Arija, H.P. Gurney, N. Matsubara, L.W. Liang, J. Todoric, K. Imai, A. Stenzl
Journal: Annals of Oncology (2023)
1749P Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Authors: B. Fervers, C. Bouffay, O. Pérol, M. Bac, J. Lesage, M. Mazeron, P. Vidican, N. Moumjid
Journal: Annals of Oncology (2023)

The situation of caregiving can lead the informal family caregiver to neglect his or her own health, develop "risky” behaviours (smoking, alcohol consumption), adopt an unbalanced diet, encourage a sedentary lifestyle, and thus increase the risk of cancer. The sharing of the same lifestyle, including the same risk factors, within the informal family caregivers-patients dyad can also increase this risk. In addition, compared to the general population, informal family caregivers have a better perception of their risks and a greater motivation to change their behaviour. The objectives of the present study are to evaluate the feasibility and acceptability of a personalised primary prevention intervention for modifiable cancer risk factors in informal family caregivers of cancer patients. The study is being conducted at the Léon Bérard Cancer Centre (Lyon, France), since April 2022, among informal family caregivers (first-degree relative or partner/spouse) who are adults and cancer-free. The personalised intervention was co-constructed with the representatives of informal family caregivers. It targets 6 risks factors (tobacco, alcohol, diet, physical activity, overweight/obesity, ultraviolet exposure) and screening. The intervention consists of an initial consultation (quantification of exposure, information on recommendations, drafting of a personalised primary prevention programme), support for the implementation and a four-month follow-up consultation (assessment of the actions taken, readjustment of the programme, exchanges to perpetuate the changes). To date, out of the 50 informal family caregivers expected, 26 have been seen at the initial consultation and 7 at the follow-up consultation. Inclusion will end in August 2023, the study looks feasible and acceptable, more results will be presented at the Congress. The PREV-CARE transferability study of this intervention at the Institut Gustave Roussy (Paris, France) began in December 2022. Its objectives are to analyse the transferability of the intervention, to meet the challenges of territorial diversity, before considering evaluation on a larger scale.
1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study
Authors: S.J. Freedland, M.E. Gleave, U.F.F. De Giorgi, A. Rannikko, C. Pieczonka, R. Tutrone, B. Venugopal, H. Woo, M. Ramirez Backhaus, S. Supiot, A. Lantz, A. Ganguli, J. Ivanova, P. Kral, S-P. Huang, F. Saad, N.D. Shore
Journal: Annals of Oncology (2023)
1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
Authors: B. Tombal, P.J. Goebell, N.D. Shore, D.J. George, A. Pinto, O. Sartor, J. Meltzer, F. Verholen, A. Schmall, F. Saad
Journal: Annals of Oncology (2023)
1796P Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Authors: J. Gómez Rivas, R. Nicoletti, A. Golozar, C. Steinbeißer, L. Ibañez, B. De Meulder, S. Evans Axelsson, R. Snijder, A. Bjartell, P. Cornford, P-P. Willemse, P. Prinsen, T. Murtola, J. N'Dow
Journal: Annals of Oncology (2023)
1779P PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Authors: G. Francolini, C. Orsatti, V. Di Cataldo, B. Detti, S. Caini, M. Banini, L. Caprara, L. Burchini, G. Frosini, M. Loi, G. Simontacchi, D. Greto, C. Franzese, M. Scorsetti, A. Chiti, C. Becherini, L. Vaggelli, I. Desideri, I. Meattini, L. Livi
Journal: Annals of Oncology (2023)
1748P Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Authors: K.V. Kamposioras, K. Marti, S. Droufakou, D. Spiteri, P. Marti, P. Kountourakis, L. Lorioli, None M. tolia, D. Mauri, R. Alves
Journal: Annals of Oncology (2023)
1745P Why do adult patients with cancer abandon treatment in India? A nationwide qualitative study to understand the perspectives of healthcare workers
Authors: R. Ayiraveetil, M. Chittem, S. Lakshminarayanan, S. Veeraiah, P. Penumadu, J. Pandjatcharam, S. Kayal, B. Dubashi, P. Ganesan
Journal: Annals of Oncology (2023)
1741P Are physicians aware of lung cancer screening benefits and the importance of implementing this? Data from two public hospitals in Buenos Aires province, Argentina
Authors: V. Vidal, F. Durante, A. González Saénz, J. Hernández, E. Carinci, L.V. Fornero, A. Daza, M. Lavezzaro, M.D. Aguiar
Journal: Annals of Oncology (2023)
1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Authors: U.F.F. De Giorgi, S.J. Freedland, M.E. Gleave, R. Tutrone, J.L. Bailen, E. Roos, J. Kliment, G.M. Marx, L.I. Karsh, M. Ramirez-Backhaus, E. Uchio, S. Supiot, Y. Tang, B. Rosbrook, G.P. Haas, M. Rosales, F. Zohren, N.D. Shore
Journal: Annals of Oncology (2023)
1735P Impact of revised US Preventive Services Task Force (USPSTF) 2021 lung cancer screening guideline on long-term cancer survivors in the United States
Authors: Q. Wang, C. Wen, M.L. Hsu, C. Jiang, L. Deng, H. Xie, Y. Li, Y. Zhang, A. Dowlati, D. Bruno, L. Chiec, G. Dutcher, C.Y. Kong
Journal: Annals of Oncology (2023)
1730P Dealing with digital paralysis: Surviving a cyberattack in a cancer centre
Authors: R.J. Keogh, H.M. Harvey, C. Brady, E. Hassett, S.J. Costelloe, M.J. O’Sullivan, M. Twomey, M.J. O'Leary, M.R. Cahill, A. O'Riordan, C.M. Joyce, A. Flavin, R. Bambury, D. Murray, K. Bennett, M. Mullooly, S. O'Reilly
Journal: Annals of Oncology (2023)
1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Authors: H. Gelderblom, A. Edsjö, H.E.G. Russnes, U.N. Lassen, A. Helland, E. Hallersjö Hult, B. Ryll, I. Lugowska, J-Y. Blay, R.S. Falk, S. van Waalwijk van Doorn-Khosrovani, K. Steen Carlsson, K. Peltola, A. Stenzinger, E. Vrdoljak, J. Oliveira, S.F. Haj Mohammad, H.M.W. Verheul, E.E. Voest, K. Tasken
Journal: Annals of Oncology (2023)
1671P Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Authors: T. Macarulla, A.J. Munoz Martin, E. Martinez de Castro, A.O. Castillo Trujillo, M.T. Cano Osuna, C. Fabregat, R. Vidal Tocino, J. Gallego Plazas, I. Ghanem, I.C. Ales Diaz, R. Vera, M. Lobo de Mena, J. Adeva Alfonso, M. Melian, I. Gallego Jimenez, B. Laquente, A. Fernandez Montes, P. Peinado Martin, A. Carrato Mena, E. Aranda Aguilar
Journal: Annals of Oncology (2023)
1649P Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Authors: E. So, H. Hayashi, K. Shimozaki, S. Horie, S. Kishimoto, A. Chida, Y. Saito, K. Tsugaru, K. Hirata, H. Nishihara, T. Kanai, Y. Hamamoto
Journal: Annals of Oncology (2023)
1648P Association between circulating tumor cell count and thrombosis in pancreatic cancer
Authors: M. Benavente, N. Gutierrez Alonso, M. Bringas Beranek, J. Soto Alsar, M. Palma, M.A. Cañete Muñoz, C. López Jiménez, A. Gutierrez Ortiz, D.S. Juliao Caamaño, A. Lopez Alfonso, L. Ortega Morán, G. Torres Perez-Solero, D. Megias, P.A. Calvo Ferrandiz, M. Del Monte-Millan, P. Rahimi Mousavi, M. Roche-Molina, P. García Alfonso, M. Martin Jimenez, A.J. Munoz Martin
Journal: Annals of Oncology (2023)
1666P Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-Institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI)
Authors: C. Pinto, M. Milella, F. Bergamo, M.C. Di Marco, G.G. Cardellino, L. Cavanna, E. Giommoni, F. Zustovich, M. Bonomi, S. Bozzarelli, G. Vicario, E. Parlagreco, G.L. Frassineti, M. Macchini, G. Orsi, A. Santoni, L. Caldirola, I. De Simone, M. Reni
Journal: Annals of Oncology (2023)
1664P Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Authors: M. Reni, E. Giommoni, F. Bergamo, L. Cavanna, T.P. Latiano, M. Spada, I. Bernardini, S.S. Cordio, F. Simionato, A. Spallanzani, M.C. Di Marco, N. Silvestris, M. Macchini, G. Orsi, M. Modesti, L. Procaccio, A. Santoni, L. Caldirola, F. Galli, C. Pinto
Journal: Annals of Oncology (2023)
1713P Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Authors: R.B. Barreto, M.H. Furlanetto Miranda, B.A. Uliana, L.H.D.A. Lazzari, D. Bodnar, C.M. Blatt, M.D.S. Cadore
Journal: Annals of Oncology (2023)
1726P Optimizing oncology drug spending in a cancer centre in Ireland
Authors: R. Kieran, K. Coakley, T. Cronin, C.S. Weadick, B. Macanovic, R.J. Keogh, D. Lynch, M.A. Hennessy, K. Cooke, E. Mulroe, H.M. O'Sullivan, D.C. Collins, S. O'Reilly
Journal: Annals of Oncology (2023)
1702P Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022
Authors: J.W.G. Derksen, D. Martins Branco, A. Pellat, S.C.M.W. van Nassau, A. Valachis, A. Aggarwal, M. Koopman, G. Pentheroudakis, L. Castelo-Branco, S. Delaloge
Journal: Annals of Oncology (2023)
1725P Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations
Authors: J.M. McCrary, E. Van Valckenborgh, J. van Rooij, K. Van Steen, M. Vaht, A. Metspalu, A. Uitterlinden, M. Genuardi, H.A. Poirel, A.K. Bergmann
Journal: Annals of Oncology (2023)
DIVE: a reference-free statistical approach to diversity-generating and mobile genetic element discovery
Authors: Jordi Abante, Peter L. Wang, Julia Salzman
Journal: Genome biology (2023)

Abstract Diversity-generating and mobile genetic elements are key to microbial and viral evolution and can result in evolutionary leaps. State-of-the-art algorithms to detect these elements have limitations. Here, we introduce DIVE, a new reference-free approach to overcome these limitations using information contained in sequencing reads alone. We show that DIVE has improved detection power compared to existing reference-based methods using simulations and real data. We use DIVE to rediscover and characterize the activity of known and novel elements and generate new biological hypotheses about the mobilome. Building on DIVE, we develop a reference-free framework capable of de novo discovery of mobile genetic elements.
1712P Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Authors: J.J. Soto Castillo, L. Notario Rincon, D. Azuara, J.C. Ruffinelli, A. Stradella, M. Oliva Bernal, M. Calvo Campos, M. Jové, S. Llop Serna, R. Villanueva Vazquez, C. Cuadra Amor, M.A. Bergamino, E. Teixidor Vilà, S. Villatoro Gómez, M. González Acosta, C. Fina Planas, C. Hierro, M. Gil Martín, C. Lazaro, J. Martin-Liberal
Journal: Annals of Oncology (2023)
1722P Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases
Authors: T. Sanomachi, T. Shimoi, A. Kawachi, H.S. Okuma, M. Hoshino, M. Ito, A. Saito, S. Kita, A. Maejima, Y. Kojima, T. Nishikawa, E. Nakamura, K. Sudo, K. Yonemori
Journal: Annals of Oncology (2023)
1643P Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Authors: K. Bang, H. Yoon, J.H. Lee, D.W. Hwang, K.B. Song, S.C. Kim, B-Y. Ryoo, K-P. Kim, C. Yoo
Journal: Annals of Oncology (2023)
1710P Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Authors: L.J. Zeverijn, J.M. van Berge Henegouwen, B.S. Geurts, G.F. de Wit, L. Hoes, H. van der Wijngaart, V. van der Noort, A.D.R. Huitema, F.Y.F.L. De Vos, K. Grunberg, H. Bloemendal, H.M.W. Verheul, E.E. Voest, H. Gelderblom
Journal: Annals of Oncology (2023)
1724P Improving access to breast cancer diagnosis and treatment through navigation: Evaluation of a one-year pilot project in Botswana
Authors: A. Migeotte, I. Soares de Pinho, N. Ngwako, T. Leselwa, T. Lethloma, T. Ralefala, I. Setlhako, N.C. Swart, J. Khutjwe, T. Gaolathe, R. Lebelonyane, K.M. Chalegwa, P. Moanakwena, R. Marlink, K. Sharma, P. Vuylsteke
Journal: Annals of Oncology (2023)
1685TiP Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Authors: J.L. van Dam, E.M.M. Verkolf, E.N. Dekker, G. van Tienhoven, M.Y.V. Homs, M.G. Besselink, H.W. Wilmink, B. Groot Koerkamp
Journal: Annals of Oncology (2023)
1679P Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Authors: L. Mastrantoni, V. Beccia, M. Chiaravalli, A. Di Bello, A. Spring, D. Barone, F. Schietroma, M.G. Maratta, G. Trovato, C. Bagalà, M. Bensi, S. Alfieri, G. Quero, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2023)
1658P Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Authors: J. Earl, E. Barreto, M. Rodriguez, J. Villalon López, R. Fuentes Mateos, A. Garcia García de Paredes, A. Sanjuanbenito, E. Lobo, I. Ruz-Caracuel, M. Muñoz Beltran, E. Ramos, J. Blaquez, A. Carrato Mena
Journal: Annals of Oncology (2023)
1687O PRIMCAT: A novel approach to informing health technology assessment decision making in Australia
Authors: F. Franchini, K. Trapani, J. Soon, B. Daniels, P. Gillett, K. Degeling, M. Alexander, Y.H. To, S. O'Haire, O. Yang, S. Fox, J. Desai, Y. Zhang, B.J. Solomon, P. Gibbs, G. McArthur, S. Pearson, M. IJzerman
Journal: Annals of Oncology (2023)
1693MO The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study
Authors: S. Janssen, C. Vlooswijk, R. van Leeuwen, S. Kaal, J.M. Kerst, J. Tromp, M.M.E.M. Bos, T. Van Der Hulle, R.I. Lalisang, J. Nuver, M. Kouwenhoven, W.T.A. Van Der Graaf, O. Husson
Journal: Annals of Oncology (2023)
1654P Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Authors: N. Gutierrez Alonso, M. Benavente, M. Bringas Beranek, J. Soto Alsar, M. Palma, M.A. Cañete Muñoz, A. Lopez Alfonso, P. Rahimi Mousavi, M. Roche-Molina, M. Del Monte-Millan, D. Megias, Á. García Pérez, L.A. Mullor Delgado, L. Ortega Morán, G. Torres Perez-Solero, B.I. Morón, P.A. Calvo Ferrandiz, P. García Alfonso, M. Martin Jimenez, A.J. Munoz Martin
Journal: Annals of Oncology (2023)
1670P Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Authors: A.R. Cardozo, R. Teres Lleida, A. Villalba, J. Gavira Diaz, J. Sanz Beltran, M.A. Molina Pérez, F. Bosma, S. Sanchez Del Rio, J.C. Tapia, A. Piedra, M. Aguado Sorolla, F.J. Pelegrín Mateo, B. Martin Cullell, D. Paez, P. Cerda Serda
Journal: Annals of Oncology (2023)
1684TiP PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Authors: P. Cassier, C. Cropet, C. Coutzac, P. Rochefort, A. Streichenberger, M. Chastenet, A. Buisson, G. Garin, D. Tatu, M. Bernardin, M. Chauvenet, F. Ghiringhelli, G. Roth, D. Perol
Journal: Annals of Oncology (2023)
1650P Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Authors: D.A. Acosta Eyzaguirre, C. Fabregat-Franco, F. Castet, D.E. López Valbuena, G. Castillo, S. Vega, S. Aguilar Izquierdo, A. Sierra, T. Tian, A. Vivancos, R. Dienstmann, T. Macarulla
Journal: Annals of Oncology (2023)